- Joined
- Feb 25, 2004
- Messages
- 893
- Reaction score
- 1
I was reading the Canadian edition of the most recent Reader's Digest when I came across a news item which said that a new form of insulin delivery has recently been developed.
This inhaled form of insulin, Exubera,is a rapid-acting insulin which is effective for both forms of diabetes. It will eliminate the painstaking task many diabetics have to tolerate with their daily subcutaneous insulin injections. However, there have been concerns in regards to the long term effects of this medication on pulmonary function so it has been contraindicated in those individuals afflicted with asthma, bronchitis, or emphysema. It will be available sometime this year.
Compared with patients who received only insulin injections, patients receiving Exubera experienced significant reductions in both fasting plasma glucose levels (blood glucose measured before breakfast) and two-hour post-prandial glucose levels (blood glucose measured after meals). Patients also preferred using Exubera, were more satisfied with their overall treatment and showed greater improvements in symptoms and cognitive function (assessed by the Diabetes Quality of Life and Treatment Satisfaction questionnaire).
http://www.drugdevelopment-technology.com/projects/exubera/
http://www.diabetesmonitor.com/pr61.htm
This inhaled form of insulin, Exubera,is a rapid-acting insulin which is effective for both forms of diabetes. It will eliminate the painstaking task many diabetics have to tolerate with their daily subcutaneous insulin injections. However, there have been concerns in regards to the long term effects of this medication on pulmonary function so it has been contraindicated in those individuals afflicted with asthma, bronchitis, or emphysema. It will be available sometime this year.
Compared with patients who received only insulin injections, patients receiving Exubera experienced significant reductions in both fasting plasma glucose levels (blood glucose measured before breakfast) and two-hour post-prandial glucose levels (blood glucose measured after meals). Patients also preferred using Exubera, were more satisfied with their overall treatment and showed greater improvements in symptoms and cognitive function (assessed by the Diabetes Quality of Life and Treatment Satisfaction questionnaire).
http://www.drugdevelopment-technology.com/projects/exubera/
http://www.diabetesmonitor.com/pr61.htm